The role of miR-497-5p in myofibroblast differentiation of LR-MSCs and pulmonary fibrogenesis.

Sci Rep

Immunology and Reproduction Biology Laboratory &State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China.

Published: January 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal fibrotic lung disease characterized by profound changes in stem cell differentiation, epithelial cell phenotypes and fibroblast proliferation. In our study, we found that miR-497-5p was significantly upregulated both during myofibroblast differentiation of lung resident mesenchymal stem cells (LR-MSCs) and in the lung tissues of a pulmonary fibrosis model. In addition, as determined by luciferase assays and Western blot analysis, reversion-inducing cysteine-rich protein with kazal motifs (Reck) was identified to be one of the target genes of miR-497-5p, and Reck could suppress the expression of matrix metalloproteinase-2 (Mmp2) and Mmp9, which could activate latent transforming growth factor-β1 (TGF-β1). To test the potential therapeutic significance of this miRNA, we modulated the expression of miR-497-5p in LR-MSCs and relevant animal models. The results demonstrated that upregulation of miR-497-5p could induce LR-MSCs to differentiate into myofibroblasts and promote pulmonary fibrogenesis, while inhibition of its expression could effectively retard these processes. In conclusion, our work supports that controlling pulmonary fibrogenesis via inhibition of miR-497-5p expression may provide a potential therapeutic strategy for IPF.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241881PMC
http://dx.doi.org/10.1038/srep40958DOI Listing

Publication Analysis

Top Keywords

pulmonary fibrogenesis
12
myofibroblast differentiation
8
pulmonary fibrosis
8
potential therapeutic
8
fibrogenesis inhibition
8
pulmonary
5
mir-497-5p
5
role mir-497-5p
4
mir-497-5p myofibroblast
4
lr-mscs
4

Similar Publications

Fibrotic lung diseases are associated with significant morbidity and mortality, and few therapies have been FDA-approved for patients with these conditions. Therefore, developing effective anti-fibrotic treatments represents an unmet clinical need. Plasminogen activator inhibitor 1 (PAI-1) is an attractive therapeutic target as its expression is up-regulated in the context of fibrotic lung disease, and a causal role for PAI-1 in lung fibrogenesis has been established in complementary animal models.

View Article and Find Full Text PDF

Overexpression miR-125a-5p inhibits HSCs activation and alleviates liver fibrosis through TGF-β/Smad2/3 signaling pathway and autophagy.

Cell Death Discov

September 2025

State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary Fibrosis, Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis, College of Life Science, Institute of Biomedical Science, Henan Normal University, Xinxiang, Henan, China. guo

Liver fibrosis represents an important pathological stage during chronic hepatopathy development, posing a significant threat to human health. Hepatic stellate cells (HSCs), an essential hepatic non-parenchymal cells, have a key effect on fibrogenesis, with their activation being a hallmark of liver fibrosis. MicroRNAs (miRNAs), the small non-coding RNAs, become the critical biomarkers and regulatory molecules in fibrotic processes.

View Article and Find Full Text PDF

From senescence to scarring: Exploring TGF-β signaling in cellular aging, fibrotic remodeling, and pulmonary fibrosis.

Cytokine Growth Factor Rev

August 2025

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Sarojini Nagar, Near CRPF Base Camp, Lucknow, Uttar Pradesh 226002, India. Electronic address:

Cellular senescence and the formation of fibrotic scarring are critical in the progression of chronic illnesses, such as pulmonary fibrosis (PF). In this context, the transforming growth factor-beta (TGF-β) pathway represents a central driver in orchestrating the pathological cascade. TGF-β governs cellular activities such as differentiation, apoptosis, and extracellular matrix (ECM) remodeling as a pleiotropic cytokine.

View Article and Find Full Text PDF

Clonal expansion of alveolar fibroblast progeny drives pulmonary fibrosis in mouse models.

J Clin Invest

August 2025

Division of Pulmonary and Critical Care Medicine, UCSF, San Francisco, United States of America.

Pulmonary fibrosis has been called a fibroproliferative disease but the functional importance of proliferating fibroblasts to pulmonary fibrosis has not been systematically examined. In response to alveolar injury, resting alveolar fibroblasts differentiate into fibrotic fibroblasts that express high levels of collagens. However, what role, if any, proliferation plays in the accumulation of fibrotic fibroblasts remains unclear.

View Article and Find Full Text PDF

Glycolysis to lactylation: Unraveling the metabolic and epigenetic landscape in tissue fibrosis (Review).

Mol Med Rep

November 2025

Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.

Tissue fibrosis represents a pathological condition characterized by excessive accumulation of extracellular matrix (ECM) components. Although historically considered a byproduct of glycolysis, lactate has emerged as a key signaling molecule influencing diverse physiological and pathological processes, including fibrosis. Roles have emerged for lactate metabolism and lactylation, a novel post‑translational modification, in regulating fibroblast activation, ECM deposition and fibrotic progression.

View Article and Find Full Text PDF